Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | G6PD | P11413 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48723 | 1.00 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL27925721 | 1.00 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL15869337 | 1.00 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL26108766 | 0.98 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL28508112 | 0.98 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2285638 | 0.98 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| Hydrazine SCHEMBL28369279 | 0.98 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL8070950 | 0.98 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL8070939 | 0.98 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28051606 | 0.96 | MMP2 (0.59) | MMP2G6PDCASP7CASP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598969-A1 | FUNCTIONALIZED MACROMOLECULES AND SYSTEMS, METHODS OF SYNTHESIS, AND USES THEREOF | Seer, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-3619195-B1 | NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE | UNICHEM LAB LTD (IN) | 2025-07-23 | — | — | EP | claimed |
| WO-2025101535-A1 | BIOMOLECULE CLEANUP METHODS, KITS, AND SYSTEMS | SEER, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20240384002-A1 | METHODS FOR SITE SPECIFIC CONJUGATION OF PROTEINS CONTAINING GLYCOSYLATED Fc DOMAINS | JANSSEN BIOTECH, INC. | 2024-11-21 | — | — | US | claimed |
| US-12084475-B2 | Methods for site specific conjugation of proteins containing glycosylated Fc domains | JANSSEN BIOTECH, INC. (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024077009-A1 | FUNCTIONALIZED MACROMOLECULES AND SYSTEMS, METHODS OF SYNTHESIS, AND USES THEREOF | SEER, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| CN-116887607-A | Method for improving thermal stability of perovskite solar cell | 河北工业大学 | 2023-10-13 | — | — | CN | claimed |
| US-20260133184-A1 | OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) | BINARY LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624026-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12568986-B2 | Method of reducing acrylamide in coffee extract and a soluble coffee product | KONINKLIJKE DOUWE EGBERTS B.V. (NL) | 2026-03-10 | — | — | US | disclosed |
| US-20260063624-A1 | OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) | BINARY LLC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260056193-A1 | FUNCTIONALIZED MACROMOLECULES AND SYSTEMS, METHODS OF SYNTHESIS, AND USES THEREOF | SEER INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-11331020-B2 | Enzyme-based electrochemical nicotine biosensor | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3990900-A1 | OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) | Binary LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-108495563-B | Nicotine salts, co-crystals and salt co-crystal complexes | R.J.雷诺兹烟草公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220047639-A1 | Method of Preparing Hematopoietic Stem and Progenitor Cells for Transplantation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2022-02-17 | — | — | US | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| CN-114002207-A | Application of ascorbic acid peroxidase 1 in catalysis of luminol chemiluminescence reaction | 浙江大学 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624026-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, NNMT | MMP2 653/4885G6PD 3334/4885CASP7 2748/4885 |
| US-20260063624-A1 | OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) | MPO, NOX3, NOX1 | MMP2 702/4885G6PD 66/4885CASP7 487/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | MMP2 91/4885G6PD 499/4885CASP7 357/4885 |
| US-20260056193-A1 | FUNCTIONALIZED MACROMOLECULES AND SYSTEMS, METHODS OF SYNTHESIS, AND USES THEREOF | CPS1, CA6, SMC2 | MMP2 2449/4885G6PD 52/4885CASP7 4126/4885 |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DMPK, KRTCAP2 | MMP2 4048/4885G6PD 3430/4885CASP7 3737/4885 |
| US-20260133184-A1 | OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) | MPO, MYADM, CD14 | MMP2 1059/4885G6PD 71/4885CASP7 366/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | MMP2 2979/4885G6PD 2060/4885CASP7 3451/4885 |
| US-12568986-B2 | Method of reducing acrylamide in coffee extract and a soluble coffee product | ACR, ADCY10, CIP2A | MMP2 888/4885G6PD 3746/4885CASP7 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.